Requires the labeling of certain baby cosmetic products
A11360 would amend New York’s General Business Law to create new labeling requirements for infant cosmetic products, defined broadly to include lotions, creams, moisturizers, ointments, oils, and similar products marketed for infants or young children. The bill requires any such product sold in New York to display a clear and conspicuous ingredient list in order of predominance, printed in at least 12-point font and placed on the packaging or attached to it.
The bill also adds a specific warning-label requirement for infant cosmetic products that contain a carcinogen. In that case, the packaging or product itself must carry a conspicuous warning in at least 12-point font stating: “This product contains a chemical known to cause cancer.” Manufacturers are made responsible for compliance, and the Attorney General may seek injunctions and civil penalties for violations. The measure would take effect 180 days after becoming law.
If enacted, the bill would add a new section to the General Business Law governing the sale of infant cosmetic products in New York. It would impose affirmative labeling duties on manufacturers and sellers of baby lotions and similar products, requiring ingredient disclosure and cancer warnings where applicable, and would authorize enforcement by the Attorney General through injunctions and civil penalties of up to $250 for a first offense and $500 for subsequent offenses. The bill would affect manufacturers, packagers, distributors, and retailers of infant personal care products sold in the state.
The available record shows limited formal debate, as there are no committee transcripts or recorded votes attached to the bill. Based on the bill’s purpose and structure, the measure appears to be framed as a consumer protection and child safety proposal, with an emphasis on transparency about ingredients and potential carcinogenic exposure in products used on infants and young children. The absence of recorded opposition or support makes the overall sentiment difficult to gauge beyond the bill’s protective intent.
The main points of potential contention are likely to be the scope of the labeling mandate, the burden placed on manufacturers, and the practical implications of requiring a cancer warning on products containing any carcinogen. Industry stakeholders may object to compliance costs, packaging changes, and the breadth of the definition of infant cosmetic product or carcinogen-triggered warnings. Consumer advocates, by contrast, would likely support the measure as a transparency and health-protection requirement for products used on vulnerable children.